DNA-methylation and genomic copy number in primary tumors and corresponding lymph node metastases in prostate cancer from patients with low and high Gleason score

[1]  Trevor J Pugh,et al.  The cell-free DNA methylome captures distinctions between localized and metastatic prostate tumors , 2022, Nature Communications.

[2]  F. Fabozzi,et al.  Pediatric Diffuse Midline Gliomas: An Unfinished Puzzle , 2022, Diagnostics.

[3]  P. Hu,et al.  Epigenome-wide DNA methylation and transcriptome profiling of localized and locally advanced prostate cancer: Uncovering new molecular markers. , 2022, Genomics.

[4]  D. Low,et al.  The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial , 2022, The Lancet.

[5]  Wei-Qiang Gao,et al.  The evolving role of immune cells in prostate cancer. , 2021, Cancer letters.

[6]  Tianshu Yang,et al.  Snail/PRMT5/NuRD complex contributes to DNA hypermethylation in cervical cancer by TET1 inhibition , 2021, Cell Death & Differentiation.

[7]  S. Kannan,et al.  Prostate-Only Versus Whole-Pelvic Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer (POP-RT): Outcomes From Phase III Randomized Controlled Trial. , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  F. Deng,et al.  The Landscape of Immune Cells Infiltrating in Prostate Cancer , 2020, Frontiers in Oncology.

[9]  Luke A. Gilbert,et al.  DNA methylation landscapes in advanced prostate cancer , 2020, Nature Genetics.

[10]  Xiaoqi Liu,et al.  Epigenetic regulation of prostate cancer , 2019, Genes & diseases.

[11]  R. Cardiff,et al.  The comprehensive role of E-cadherin in maintaining prostatic epithelial integrity during oncogenic transformation and tumor progression , 2019, PLoS genetics.

[12]  N. Xu,et al.  Identification of key DNA methylation-driven genes in prostate adenocarcinoma: an integrative analysis of TCGA methylation data , 2019, Journal of Translational Medicine.

[13]  Zhao Chen,et al.  Regulation of prostate cancer by hormone‐responsive G protein‐coupled receptors , 2018, Pharmacology & therapeutics.

[14]  Adam P Dicker,et al.  Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial. , 2018, The Lancet. Oncology.

[15]  B. Ali,et al.  DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer , 2018, Clinical Epigenetics.

[16]  Yiping Li,et al.  DNA methyltransferase 3A isoform b contributes to repressing E-cadherin through cooperation of DNA methylation and H3K27/H3K9 methylation in EMT-related metastasis of gastric cancer , 2018, Oncogene.

[17]  E. Goetghebeur,et al.  Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  J. Davie,et al.  Ubiquitin C-terminal hydrolase isozyme L1 is associated with shelterin complex at interstitial telomeric sites , 2017, Epigenetics & Chromatin.

[19]  A. Meeker,et al.  Telomeres and telomerase in prostate cancer development and therapy , 2017, Nature Reviews Urology.

[20]  K. Pienta,et al.  A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE) , 2017, BMC Cancer.

[21]  Y. Bignon,et al.  Global analysis of H3K27me3 as an epigenetic marker in prostate cancer progression , 2017, BMC Cancer.

[22]  I. Mills,et al.  The importance of DNA methylation in prostate cancer development , 2017, The Journal of Steroid Biochemistry and Molecular Biology.

[23]  D. Pérol,et al.  Is There a Role for Pelvic Irradiation in Localized Prostate Adenocarcinoma? Update of the Long-Term Survival Results of the GETUG-01 Randomized Study. , 2016, International journal of radiation oncology, biology, physics.

[24]  J. Ellinger,et al.  Alterations of Global Histone H3K9 and H3K27 Methylation Levels in Bladder Cancer , 2014, Urologia Internationalis.

[25]  Jing Shen,et al.  DNA methylation changes correlate with Gleason score and tumor stage in prostate cancer. , 2012, DNA and cell biology.

[26]  M. Roach,et al.  Pelvic nodal radiotherapy in patients with unfavorable intermediate and high-risk prostate cancer: evidence, rationale, and future directions. , 2011, International journal of radiation oncology, biology, physics.

[27]  M. Piérart,et al.  Duration of androgen suppression in the treatment of prostate cancer. , 2009, The New England journal of medicine.

[28]  Sylvie Chabaud,et al.  Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Charles R. Thomas,et al.  An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. , 2007, International journal of radiation oncology, biology, physics.

[30]  Charles R. Thomas,et al.  Whole-pelvis, "mini-pelvis," or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial. , 2006, International journal of radiation oncology, biology, physics.

[31]  R K Valicenti,et al.  Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  A. Heidenreich,et al.  Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. , 2002, The Journal of urology.

[33]  D. Grignon,et al.  Four prognostic groups predict long-term survival from prostate cancer following radiotherapy alone on Radiation Therapy Oncology Group clinical trials. , 2000, International journal of radiation oncology, biology, physics.

[34]  Siwei Wang,et al.  H3K27 trimethylation and H3K9 dimethylation as poor prognostic markers for patients with esophageal squamous cell carcinoma. , 2019, International journal of clinical and experimental pathology.

[35]  T. Ichida,et al.  World Medical Association declaration of Helsinki , 2008, Gastroenterologia Japonica.

[36]  P. Carroll,et al.  Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. , 1994, International journal of radiation oncology, biology, physics.